Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Could 7 days of dual blood thinners be enough for elderly heart patients?

NCT ID NCT07164859

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether older adults (65+) who get a heart stent can safely stop one of their blood thinners (aspirin) after just 7 days instead of the usual 3 to 12 months. The goal is to see if this shorter treatment reduces bleeding risks without increasing heart attacks, strokes, or death. About 1,700 participants will be randomly assigned to either the short or standard treatment and followed for one year.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 1,700 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2025

An estimate. Start dates often move.

Expected to finish

Oct 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

65 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients ≥ 65 years * Successfully treated with percutaneous coronary intervention (PCI) with ≥ 1 drug-eluting stent (final TIMI 3 flow and visually estimated residual diameter stenosis \<30%) for acute coronary syndrome (including ST-elevation myocardial infarction, non-ST-elevation myocardial infarction and unstable angina) or chronic coronary syndrome (elective PCI). Inclusion is possible after the last PCI procedure in staged procedure. * Randomization must be performed before the discharge from the study site. * Written informed consent * Social security affiliated Exclusion Criteria: * PCI without drug-eluting stent implantation or with a bioresorbable scaffold * Planned coronary artery bypass grafting or cardiac surgery * Any planned surgery within 12 months unless intended antiplatelet therapy could be maintained throughout the peri-surgical period * Index PCI for stent thrombosis or chronic total occlusion * Need for oral anticoagulation therapy * Known hypersensitivity or allergy to aspirin, clopidogrel, ticagrelor or prasugrel * Use of fibrinolytic therapy within 24 hours of PCI * Severe renal insufficiency (MDRD creatinine clearance \< 30 ml/min/m2) and/or dialysis * Increased bleeding risk (prior hemorrhagic stroke; stroke \< 30 days; brain injury\<6 months; history of intracranial tumor or intracranial hemorrhage; internal bleeding\<6 weeks; active bleeding; anemia (hemoglobin ≤ 8 g/dl) or thrombocytopenia (platelets \< 100 000 G/L); major surgery\<3 weeks) * increased thrombotic risk related to the patient (previous stent thrombosis, ≥ 2 previous myocardial infarction, symptomatic peripheral artery disease, chronic systemic inflammatory disease treated with corticoids or immunosuppressive drug) or the procedure (left main treated, ≥3 stents/treated lesions, total length of stents\>60mm, bifurcation lesion with stents in each branch, stenting of the last patent vessel) * Life expectancy less than 1 year * Participation in another interventional trial * Patients considered as vulnerable by the investigators because of medical, psychological or social conditions: * Patients with known or discovered severe cognitive impairment * Patients with treated or untreated severe psychological or psychiatric conditions * Patients with uncorrected severe hearing or visual handicap * Patients with addictive alcohol, drug or substance abuse * Patients with protective measures (guardianship, tutorship, curatorship) * Any other condition considered by the investigators as not warranting informed consent * patients with poor quality of the downstream territory with diffuse distal coronary disease * women of childbearing potential: non menopaused -with no menses for 12 months without an alternative medical cause- and not permanently sterilized -hysterectomy, bilateral salpingectomy or bilateral oophorectomy-

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Antiplatelet therapy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Caen University Hospital

    Caen, 14000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.